ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2467

Tissue Lesions in Osteoarthritis Initiative Participants with Normal X-Rays and Risk Factors for Incident Cartilage Damage

Leena Sharma1, Ali Guermazi2, Orit Almagor1, Michel Crema2, Dorothy D. Dunlop3, Frank Roemer4, Marc C. Hochberg5, Charles Eaton6, Joan M. Bathon7, Rebecca D. Jackson8, W.J. Mysiw8, C. Kent Kwoh9, Michael C. Nevitt10 and Joan S. Chmiel1, 1Northwestern University, Chicago, IL, 2Boston University, Boston, MA, 3Northwestern University Feinberg School of Medicine, Chicago, IL, 4Klinikum Augsburg, Augsburg, Germany, 5Department of Medicine, University of Maryland, Baltimore, MD, 6Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Providence, RI, 7Columbia University, New York, NY, 8Ohio State University, Columbus, OH, 9School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 10Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: cartilage, Epidemiologic methods, Knee, magnetic resonance imaging (MRI) and osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoarthritis - Clinical Aspects II: Structural Risks for Osteoarthritis End-points and Potential Treatments

Session Type: Abstract Submissions (ACR)

Background/Purpose: Understanding factors underlying initial development of knee OA is crucial to effective prevention strategy design.  Our goals were to: 1) determine extent of tissue damage on MRI in knees of persons at higher risk for knee OA and in whom both knee x-rays were normal (KL 0); and 2) evaluate whether presence of any bone marrow lesions (BML), meniscal tears (MT), meniscal extrusion (ME), or hand OA is associated with risk of incident cartilage damage.

Methods: The Osteoarthritis Initiative (OAI) is a cohort study of men and women, 45-79 years, all with or at increased risk to develop knee OA.  850 participants had had bilateral KL 0 at 12 months (baseline for this study) by centralized reading.  On their right knee MRIs, we undertook assessment of cartilage morphology, BML, MT, and ME using a modified MOAKS scoring system.  Readers were blinded to hypotheses, clinical data, and KL grade.  The definition of hand OA relied upon number of bony enlargements.  12 and 48 month image assessments occurred within an ancillary study; in addition, OAI clinical data V6.2.1 and BU x-ray reading data V1.5 were used.  Mulitiple logistic regression models were used to evaluate associations between baseline data and incident cartilage damage by 3 year follow-up; results are reported as adjusted odds ratios (aORs) with 95% CIs.

 Results: 850 persons met criteria for inclusion [mean age 59.6 years (8.8, SD), mean BMI 26.7 kg/m2 (4.2), 475 (56%) women].  Among the 850 KL 0 knees, the number with abnormal tissue in one or more subregions at baseline was: 483 (57%) with cartilage damage (full-thickness in 67); 353 (42%) with BML; 180 (21%) with MT; and 117 (14%) with ME.  In only 56 (7%) knees were all of these tissues normal.  367 persons [age 58.5 (8.8), BMI 26.4 (4.2), 226 (62%) women] contributed 367 knees with normal cartilage morphology in all regions at baseline.  Of the 367, 80 had BML, 45 had MT (32 horizontal, 9 vertical, 4 partial maceration), and 25 had ME.  Lesions coexisted in some knees (11 with BML+MT, 7 with BML+ME, and 10 with MT+ME).  In separate models, each adjusting for age, gender, BMI, and hand OA, BML [aOR 2.24, 95% CI (1.15, 4.34)] and ME [aOR 2.83, 95% CI (1.03, 7.79)] were each associated with incident cartilage damage.  In a model including all covariates, BML continued to be significant [aOR 2.19, 95% CI (1.12, 4.28)], while ME was not quite significant [aOR 2.71, 95% CI (0.97, 7.58)].  Of note, hand OA presence was consistently associated with incident cartilage damage, e.g., in the fully adjusted model, aOR 2.30, 95% CI (1.15, 4.60) for this variable.

 Conclusion: Cartilage damage was already present in 57% of right knees from persons without OA in either knee by protocolized x-ray, but at higher risk, suggesting that radiographic studies of incident OA in this population, even restricted to KL 0, are frequently evaluating not incidence but early progression.  Among knees with normal cartilage morphology, hand OA, BML, and ME were each associated with an increased risk of incident cartilage damage.  While MRI is superior to x-ray, the optimal window for cohort studies to capture the onset of knee OA by MRI may fall earlier in the lifetime of individuals at higher risk than is being evaluated in many current studies. Prevention strategies may be most powerful at this time point.


Disclosure:

L. Sharma,
None;

A. Guermazi,

Boston Imaging Core Lab,

1,

Stryker,

5,

Merck Serono,

5,

Genzyme Corporation,

5,

AstraZeneca,

5,

Novartis Pharmaceutical Corporation,

5;

O. Almagor,
None;

M. Crema,

Shareholder Boston Imaging Core Lab, LLC,

1;

D. D. Dunlop,
None;

F. Roemer,

Boston Imaging Core Lab,

1,

National Institute of Health,

5,

Merck Serono,

5;

M. C. Hochberg,

Abbott Laboratories, Astra-Zeneca, Bioiberica S.A., Eli Lilly Inc., Genentech/Roche, Merck Inc., Novartis Pharma A.G., Pfizer Inc., Stryker LLC, Xoma.,

5;

C. Eaton,
None;

J. M. Bathon,
None;

R. D. Jackson,
None;

W. J. Mysiw,
None;

C. K. Kwoh,
None;

M. C. Nevitt,
None;

J. S. Chmiel,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tissue-lesions-in-osteoarthritis-initiative-participants-with-normal-x-rays-and-risk-factors-for-incident-cartilage-damage/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology